BioNTech SE shares slid -2.4% this afternoon. Here's what you need to know about the Large-CapBiotechnology company:
-
BioNTech SE has logged a 20.8% 52 week change, compared to 39.1% for the S&P 500
-
BNTX has an average analyst rating of buy and is -13.8% away from its mean target price of $129.66 per share
-
Its trailing earnings per share (EPS) is $-2.31, which brings its trailing Price to Earnings (P/E) ratio to -48.4. The Health Care sector's average P/E ratio is 26.07
-
The company's forward earnings per share (EPS) is $-3.38 and its forward P/E ratio is -33.1
-
The company has a Price to Book (P/B) ratio of 1.39 in contrast to the Health Care sector's average P/B ratio is 3.53
-
The current ratio is currently 9.4, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $5.37 Billion and the average free cash flow growth rate is 147.2%
-
BioNTech SE's revenues have an average growth rate of 100.4% with operating expenses growing at 69.0%. The company's current operating margins stand at 18.1%